AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

ABACAVIR AND LAMIVUDINE

11 registrations across 3 African markets— 8 active

Markets with ABACAVIR AND LAMIVUDINE

Recent registrations

Brand / ProductMarketHolderStatusExpires
Abacavir and Lamivudine Tablets USP 600 mg/300 mg
Film-Coated Tablet
🇰🇪KenyaMacleods Pharmaceuticals LimitedactiveFeb 2028
ABACAVIR_AND_LAMIVUDINE 600/300MG TABLET
TABLET
🇲🇼MalawiexpiredMar 2025
ABACAVIR_&LAMIVUDINE_DT 120/60MG DISPERSIBLE TABLET
DISPERSIBLE TABLET
🇲🇼MalawiexpiredMar 2025
ABACAVIR+LAMIVUDINE_DT 120/60MG TABLET
TABLET
🇲🇼MalawiexpiredMar 2025
Abacavil Sulfate and Lamivudine dispersible tablets
Tablets
🇹🇿TanzaniaMylan Laboratories Limitedactive
Abacavir and Lamivudine tablets for oral suspension 120/60mg
Tablets for Oral Suspension
🇹🇿TanzaniaCipla Limitedactive
Abacavir (as sulfate) /Lamivudine Tablet
Film Coated Tablet
🇹🇿TanzaniaSun Pharmaceutical Industries Ltdactive
Abacavir and Lamivudine
Tablets
🇹🇿TanzaniaHetero Labs Limitedactive
ABACAVIR/DOLUTEGRAVIR/LAMIVUDINE
Tablets
🇹🇿TanzaniaCipla Limitedactive
Abacavir (as Sulfate) USP and Lamivudine 120/60
Dispersible Tablets
🇹🇿TanzaniaCipla Limitedactive
Abacavir Sulfate / Lamivudine Tablets 600mg/300mg
Tablets
🇹🇿TanzaniaMylan Laboratories Limitedactive

ABACAVIR AND LAMIVUDINE in Africa — Regulatory Overview

ABACAVIR AND LAMIVUDINE is registered across 3 African markets with 11 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Tanzania, Malawi, Kenya. AfricaRegulatory refreshes this data daily from official government sources.

Of the 11 registrations, 8 (73%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.